Nextcure Inc
-4.84 %
-70.43 %
Yet to be announced
Company Overview
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. The company's primary focus is on developing innovative cancer treatments through their proprietary FIND-IO™ platform technology.
Their lead product candidate is NC318, a monoclonal antibody targeting Siglec-15, which is being evaluated for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, a fusion protein designed to block immune suppression mediated by LAIR-1.
Revenue Sources
PassNextCure is a pre-revenue stage biotechnology company focused on developing cancer treatments. As the company is still in the research and development phase with no commercial products yet launched, this criteria is not applicable at this time.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Based on the financial data from the last four quarters, NextCure reports zero interest income and zero interest expense. The company is currently pre-revenue and in the R&D phase of its operations. Given this stage of development, the interest ratio tests are not applicable.
Operational Ethics
PassAfter reviewing NextCure's public disclosures, SEC filings, and corporate documentation, there is no evidence of any significant ongoing associations with entities involved in human rights violations, including the state of Israel or the Chinese Communist Party.
Comments